Cancer vaccine hopeful Imugene is seeking to raise $20 million in fresh funds earmarked for the acquisition of IP and the development of clinical programs over the next three years at Ohio State University and the prestigious Minnesota-based Mayo Clinic.
It appears that investors are backing Imugene executive chairman and top-five shareholder Paul Hopper, who recently penned a $500 million deal between global pharmaceutical giant Merck & Co and Viralytics (where he is also chairman) to secure its immunotherapy cancer drug.
Loading...
Carrie LaFrenz is a senior journalist covering retail/consumer goods. She previously covered healthcare/biotech. Carrie has won multiple awards for her journalism including financial journalist of the year from The National Press Club. Connect with Carrie on Twitter. Email Carrie at carrie.lafrenz@afr.com
